As of close of business last night, GoodRx Holdings Inc.’s stock clocked out at 5.71, down -2.56% from its previous closing price of $5.86. In other words, the price has decreased by $-0.15 from its previous closing price. On the day, 2018764 shares were traded. GDRX reached its highest trading level at $5.89 during the session, while it also had its lowest trading level at $5.70.
To gain a deeper understanding of GDRX’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 3.37 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 14.09. For the most recent quarter (mrq), Quick Ratio is recorded 11.20 and its Current Ratio is at 11.20. In the meantime, Its Debt-to-Equity ratio is 0.81 whereas as Long-Term Debt/Eq ratio is at 0.80.
Upgrades & Downgrades
On September 07, 2022, Truist started tracking the stock assigning a Hold rating and target price of $6.50.
On August 12, 2022, DA Davidson started tracking the stock assigning a Neutral rating and target price of $8.DA Davidson initiated its Neutral rating on August 12, 2022, with a $8 target price.
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jan 03 when Idea Men, LLC sold 2,600 shares for $33.05 per share. The transaction valued at 85,927 led to the insider holds 0 shares of the business.
Slutsky Andrew sold 35,829 shares of GDRX for $1,160,796 on Jan 03. The President, Consumer now owns 2,884,529 shares after completing the transaction at $32.40 per share. On Dec 28, another insider, Voermann Karsten, who serves as the Chief Financial Officer of the company, sold 12,500 shares for $33.05 each. As a result, the insider received 413,182 and left with 0 shares of the company.
For the stock, the TTM Price-to-Sale (P/S) ratio is 3.06 while its Price-to-Book (P/B) ratio in mrq is 2.88.
Stock Price History:
Over the past 52 weeks, GDRX has reached a high of $48.05, while it has fallen to a 52-week low of $5.59. The 50-Day Moving Average of the stock is 6.49, while the 200-Day Moving Average is calculated to be 16.00.
It appears that GDRX traded 3.32M shares on average per day over the past three months and 2.47M shares per day over the past ten days. A total of 412.13M shares are outstanding, with a floating share count of 77.53M. Insiders hold about 5.10% of the company’s shares, while institutions hold 85.80% stake in the company. Shares short for GDRX as of Jul 14, 2022 were 18.67M with a Short Ratio of 4.06, compared to 18.01M on Jun 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 4.71% and a Short% of Float of 30.72%.
As of right now, 14 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of $0.04 for the current quarter, with a high estimate of $0.05 and a low estimate of $0.01, while EPS last year was $0.08. The consensus estimate for the next quarter is $0.06, with high estimates of $0.08 and low estimates of $0.03.
Analysts are recommending an EPS of between $0.33 and $0.21 for the fiscal current year, implying an average EPS of $0.28. EPS for the following year is $0.4, with 16 analysts recommending between $0.5 and $0.22.
In the current quarter, 15 analysts expect revenue to total $184.71M. It ranges from a high estimate of $188.9M to a low estimate of $173.3M. As of the current estimate, GoodRx Holdings Inc.’s year-ago sales were $176.63M, an estimated increase of 4.60% from the year-ago figure. For the next quarter, 15 analysts are estimating revenue of $202.86M, an increase of 4.10% less than the figure of $4.60% in the same quarter last year. There is a high estimate of $216.87M for the next quarter, whereas the lowest estimate is $183.9M.
A total of 18 analysts have provided revenue estimates for GDRX’s current fiscal year. The highest revenue estimate was $845.71M, while the lowest revenue estimate was $764.4M, resulting in an average revenue estimate of $816.38M. In the same quarter a year ago, actual revenue was $745.42M, up 9.50% from the average estimate. Based on 18 analysts’ estimates, the company’s revenue will be $981.89M in the next fiscal year. The high estimate is $1.07B and the low estimate is $885.3M. The average revenue growth estimate for next year is up 20.30% from the average revenue estimate for this year.